

CURRENT REPORT 32/2022

December 22, 2022

Allotment of series J shares

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("**Company**", "**Issuer**") with reference to Current Report No 22/2022 of 5 October 2022, Current Report No 28/2022 of 2 December 2022, Current Report No 29/2022 of 7 December 2022 and Current Report No 31 of 15 December 2022, in which the Issuer informed on the issue within the limits authorized capital of not more than 4,764,674 (in words: four million seven hundred sixty-four thousand six hundred seventy-four) ordinary bearer series J shares with the nominal value of 0.40 each ("Series J Shares") offered under the public offering conducted on the basis of the prospectus approved by the Financial Supervision Authority on 7 December 2022, informs that on 22 December 2022 the Management Board of the Company allotted all the Series J Shares offered by the Company, i.e. 4,764,674 (in words: four million seven hundred sixty-four thousand six hundred seventy-four) Series J Shares, of which:

1. 2,847,237 Series J Shares were allotted to retail and institutional investors, of which:
 - a. 30,753 were allotted to retail investors;
 - b. 2,816,484 were allotted to institutional investors.
2. 1,917,437 were allotted to BioNTech SE with its registered office in Mainz (Germany).

Cash contributions for Series J Shares were made in full by all investors to whom the Series J Shares were allotted.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board